K S Versteeg1, I R Konings1, A M Lagaay2, A A van de Loosdrecht3, H M W Verheul4. 1. Department of Medical Oncology, VU University Medical Center, Amsterdam. 2. Department of Internal Medicine, Spaarne Hospital, Hoofddorp. 3. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Medical Oncology, VU University Medical Center, Amsterdam h.verheul@vumc.nl.
Abstract
INTRODUCTION: The number of older patients with cancer is increasing. Standard clinical evaluation of these patients may not be sufficient to determine individual treatment strategies and therefore Geriatric Assessment (GA) may be of clinical value. In this review, we summarize current literature that is available on GA in elderly patients with solid malignancies who receive chemotherapy. We focus on prediction of treatment toxicity, mortality and the role of GA in the decision-making process. DESIGN: We conducted a systematic search in PubMed. Studied populations needed to fulfill the following criteria: 65 years or older, diagnosis of solid malignancy, treatment with chemotherapy, submission to GA, either designed to study prediction of treatment toxicity or mortality or to evaluate the role of GA in the decision-making process. RESULTS: Our search provided 411 publications. Thirteen met the predefined criteria. These studies revealed: (i) up to 64% of elderly patients suffer from severe toxicity caused by polychemotherapy, (ii) Nutritional status, functionality and comorbidity are often associated with worse outcome, (iii) GA reveals (unknown) geriatric problems in more than 50% of elderly patients with cancer and (iv) 21%-53% of chemotherapy regimens are being modified based on GA. CONCLUSIONS: In geriatric oncology, an accurate predictive test to guide anticancer treatment in order to prevent serious toxicity is needed. The value of GA in predicting toxicity and mortality in older patients with cancer undergoing treatment with chemotherapy has not been proven. It may be valuable in revealing geriatric problems but current evidence for its usefulness to guide treatment decisions in this setting is limited. However, we are convinced that GAs should be carried out to optimize treatment strategies in elderly patients with cancer to improve treatment efficacy and minimize toxicity.
INTRODUCTION: The number of older patients with cancer is increasing. Standard clinical evaluation of these patients may not be sufficient to determine individual treatment strategies and therefore Geriatric Assessment (GA) may be of clinical value. In this review, we summarize current literature that is available on GA in elderly patients with solid malignancies who receive chemotherapy. We focus on prediction of treatment toxicity, mortality and the role of GA in the decision-making process. DESIGN: We conducted a systematic search in PubMed. Studied populations needed to fulfill the following criteria: 65 years or older, diagnosis of solid malignancy, treatment with chemotherapy, submission to GA, either designed to study prediction of treatment toxicity or mortality or to evaluate the role of GA in the decision-making process. RESULTS: Our search provided 411 publications. Thirteen met the predefined criteria. These studies revealed: (i) up to 64% of elderly patients suffer from severe toxicity caused by polychemotherapy, (ii) Nutritional status, functionality and comorbidity are often associated with worse outcome, (iii) GA reveals (unknown) geriatric problems in more than 50% of elderly patients with cancer and (iv) 21%-53% of chemotherapy regimens are being modified based on GA. CONCLUSIONS: In geriatric oncology, an accurate predictive test to guide anticancer treatment in order to prevent serious toxicity is needed. The value of GA in predicting toxicity and mortality in older patients with cancer undergoing treatment with chemotherapy has not been proven. It may be valuable in revealing geriatric problems but current evidence for its usefulness to guide treatment decisions in this setting is limited. However, we are convinced that GAs should be carried out to optimize treatment strategies in elderly patients with cancer to improve treatment efficacy and minimize toxicity.
Authors: Kathelijn Sophie Versteeg; Susanne Blauwhoff-Buskermolen; Laurien M Buffart; Marian A E de van der Schueren; Jacqueline A E Langius; Henk M W Verheul; Andrea B Maier; Inge R Konings Journal: Oncologist Date: 2017-12-08
Authors: Thuy Koll; Mackenzi Pergolotti; Holly M Holmes; Huibrie C Pieters; G J van Londen; Zachary A Marcum; Amy R MacKenzie; Christopher B Steer Journal: Curr Oncol Rep Date: 2016-08 Impact factor: 5.075
Authors: Carolina G Vital; Raul C Maranhão; Fatima R Freitas; Brigitte M Van Eyll; Silvia R Graziani Journal: J Bone Oncol Date: 2022-04-20 Impact factor: 4.491
Authors: Nadia Yousaf; Samuel Harris; Juan Martin-Liberal; Susannah Stanway; Mark Linch; Maria Ifijen; Omar Al Muderis; Komel Khabra; Cyril Fisher; Jonathan Noujaim; Ian Judson; Charlotte Benson Journal: Clin Sarcoma Res Date: 2015-03-24
Authors: Maximilian Marhold; Thais Topakian; Hermine Agis; Rupert Bartsch; Anna S Berghoff; Thomas Brodowicz; Thorsten Fuereder; Aysegül Ilhan-Mutlu; Barbara Kiesewetter; Michael Krainer; Gottfried J Locker; Christine Marosi; Gerald Prager; Manuela Schmidinger; Christiane Thallinger; Sabine Zöchbauer-Müller; Markus Raderer; Matthias Preusser; Wolfgang Lamm Journal: ESMO Open Date: 2020-10